PBM Compensation 'Delinked' From List Price, Utilization In Medicare Part D Under Senate Bill
Legislation focuses on key aspect of Senate Finance Committee framework for reforming pharmacy benefit managers, reflecting concerns that current compensation practices reward PBMs for higher list prices and increase costs for patients. It does not take direct aim at rebates.
You may also be interested in...
Legislation to delink PBM payments from drug prices advances in House Energy and Commerce health subcommittee, putting a key pharma priority closer to the finish line. Whether patients will see any benefit remains a worry.
Pharmacy benefit managers are increasingly making money off new types of fees tied to list prices, drug industry lobby says, highlighting importance of delinking all PBM compensation from the cost of medicines. Most Congressional proposals in play do not include delinkage provision.
A focus on transparency, impacts of vertical integration and concerns about increasing government costs shows in the Congressional Budget Office score of the Senate pharmacy benefits manager reform bill.